Richmond Pharmacology is excited to attend the 2024 American HeartAssociation (AHA) Scientific Sessions in Philadelphia. This premier event incardiovascular science will bring together global leaders to present anddiscuss the latest innovations in cardiovascular research, prevention, andtreatment. The sessions will cover a wide range of topics, including basic,clinical, and population science.
To connect with our team during the event, please reach out to arrange ameeting.
Richmond Pharmacology Appoints John Hotti as Chief Technology Officer
April 22, 2026
Richmond Pharmacology is pleased to announce the appointment of John Hotti as Chief Technology Officer (CTO), strengthening the company’s leadership in technology-enabled clinical research.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
